USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: IMMUNEXT, INC.
City: LEBANON
State: NH
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase II $2,960,698.00 1
STTR Phase I $890,914.00 2

Award List:

Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease

Award Year / Program / Phase: 2012 / STTR / Phase I
Agency: HHS
Research Institution: DARTMOUTH COLLEGE
Principal Investigator: Randolph J. Noelle – 603-653-9908
Award Amount: $600,000.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The immune system depends upon an exquisite balance between positive and negative signals to maintain proper function. However, disruptions of this balance can lead to inappropriate responses: for example loss of negative regulation can result in autoimmunity.… More

Safe And Effective Anti-CD154 Antibodies For Therapeutic Intervention

Award Year / Program / Phase: 2013 / STTR / Phase I
Agency: HHS
Research Institution: DARTMOUTH MEDICAL SCHOOL
Principal Investigator: Randolph J. Noelle – 603-653-9908
Award Amount: $290,914.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): There is compelling evidence that ?CD154 treatment has great potential in autoimmunity and graft rejection. Autoimmunity. Clinical efficacy of ?CD154 treatment has been seen in Lupus and idiopathic thrombocytopenia. In addition, Principal Investigator… More

Safe and effective anti CD154 antibodies for therapeutic intervention

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Michael Rosenzweig – 617-699-0306
Award Amount: $2,960,698.00
Abstract:
DESCRIPTION (provided by applicant): In both animal proof of concept studies and preliminary clinical trials, there is ample data demonstrating the potential therapeutic benefits o CD154 blockade for treatment of GVHD, organ transplantation and autoimmunediseases. However, development of CD154 as a… More